Standard Versus Double Alpha Blockers Treatment for Symptomatic Benign Prostatic Obstruction

Standard Versus Double Alpha Blockers Treatment for Symptomatic Benign Prostatic Obstruction: A Randomized Clinical Trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07815379

Enrollment

140

Registered

2026-09-11

Start date

2025-10-12

Completion date

2026-11-01

Last updated

2026-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

BPH (Benign Prostatic Hyperplasia)

Keywords

BPH, alpha blockers, LUTS

Brief summary

Failed medical treatment to alleviate LUTS and AUR is an indication for intervention, some trials were published elucidating the possible use of standard dose tamsulosin and silodosin and double dose tamsulosin but to the best of our knowledge, no studies with head-to-head comparison between Tamsulosin and Combination of Tamsulosin and Silodosin for Management of Lower Urinary Tract Symptoms and Acute Urine Retention in Patients with Benign Prostatic Hyperplasia.

Interventions

DRUGalpha blocker monotherapy Tamsulosin

Effect of Tamsulosin and placebo in Management of Lower Urinary Tract Symptoms and Acute Urine Retention in Patients with Benign Prostatic Hyperplasia.

DRUGalpha blockers Tamsulosin and Silodosin

BPH patients are given dual alpha blockers compared to single alpha blocker drug

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

MALE

Age

40 Years to No maximum

Healthy volunteers

Inclusion criteria

Age ≥40 years. Catheterized patients due to acute urine retention secondary to BPO. Patients with moderate and severe LUTS secondary to BPH as proven by IPSS (International Prostate Symptoms score) ≥8 and Qmax \<15 ml/sec with total void urine volume \>125 cc.

Exclusion criteria

Patients with neurological problems as: uncontrolled DM, parkinsonism and cerebral stroke. Patients with history of previous prostate surgery. Patients with complicated BPH necessitating intervention as: recurrent/persistent UTI, recurrent hematuria, bladder stones and indwelling urethral catheter due to chromic urine retention (CUR). Patients with suspected malignancy by abnormal Digital Rectal Examination (DRE) and or high PSA.

Design outcomes

Primary

Measure	Time frame	Description
IPSS change	3 months	IPSS score change at 1 and 3 months following drug adminstration

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 12, 2026